Cilostazol detailed information: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 1: Line 1:
{|class="infobox" style="position: fixed; top: 180px; right: 20px; margin: 0 0 0 0; border: 0; float: right; width: 15%; background: #104E8B; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0";
|-
! style="font-size: 80%; padding: 0 5px; background: #104E8B;" | [[{{PAGENAME}}|{{fontcolor|#F8F8FF|{{PAGENAME}}®}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #000000; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|Black Box Warning}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adult Indications and Dosage|{{fontcolor|#F8F8FF|Adult Indications and Dosage}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pediatric Indications and Dosage|{{fontcolor|#F8F8FF|Pediatric Indications and Dosage}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Contraindications|{{fontcolor|#F8F8FF|Contraindications}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Warnings|{{fontcolor|#F8F8FF|Warnings}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adverse Reactions|{{fontcolor|#F8F8FF|Adverse Reactions}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Drug Interactions|{{fontcolor|#F8F8FF|Drug Interactions}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Use in Specific Populations|{{fontcolor|#F8F8FF|Use in Specific Populations}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Administration and Monitoring|{{fontcolor|#F8F8FF|Administration and Monitoring}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#IV Compatibility|{{fontcolor|#F8F8FF|IV Compatibility}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Overdosage|{{fontcolor|#F8F8FF|Overdosage}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pharmacology|{{fontcolor|#F8F8FF|Pharmacology}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Clinical Studies|{{fontcolor|#F8F8FF|Clinical Studies}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#How Supplied|{{fontcolor|#F8F8FF|How Supplied}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Images|{{fontcolor|#F8F8FF|Images}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Patient Information|{{fontcolor|#F8F8FF|Patient information}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Precautions with Alcohol|{{fontcolor|#F8F8FF|Precautions with Alcohol}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Brand Names|{{fontcolor|#F8F8FF|Brand Names}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Look-Alike Drug Names|{{fontcolor|#F8F8FF|Look-Alike Drug Names}}]]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm {{fontcolor|#F8F8FF|Drug Shortage Status}}]
|-
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price {{fontcolor|#F8F8FF|Price}}]
|-
|}
<div style="width: 80%">
__NOTOC__
__NOTOC__
{{Cilostazol}}
{{CMG}}
{{CMG}}; {{AE}} {{AZ}}


'''''For patient information, click <u>[[Cilostazol (patient information)|here]]'''''</u>.
'''''For information about (Generic Name), click [[(Generic Name)|here]].'''''


[[image:Cilo.png|900px]]
{{SB}}
 
==Disclaimer==
 
'''''WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature.  The information provided is not a medical advice or treatment.  WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer [[wikidoc:General_disclaimer|{{fontcolor|#FF0000|here}}]].'''''
 
==<span style="color:#FF0000; background:#000000;">Black Box Warning</span>==
 
FDA Package Insert for {{PAGENAME}} contains no information regarding ''Black Box Warning''.
 
{| style="border: 3px solid #696969;"
| style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" |
<center>
<font color="#F8F8FF" style="font-weight: bold;">WARNING</font>
</center>
 
<center>
<font color="#F8F8FF" size="1" style="font-style: italic;">See full prescribing information for complete boxed warning.</font>
</center>
 
<font color="#F8F8FF" style="font-weight: bold;">
''{{fontcolor|#FF0000|Condition Name:}}'' (Content)
</font>
|}


==Overview==
==Overview==
'''Cilostazol''' {{IPAc-en|s|ɨ|ˈ|l|ɒ|s|t|ə|z|ɒ|l}} is a quinolinone-derivative [[medication]] used in the alleviation of the [[symptom]] of [[intermittent claudication]] in individuals with [[peripheral vascular disease]].  It is manufactured by [[Otsuka Pharmaceutical Co.]] under the [[trade name]] '''Pletal'''.


Although drugs similar to cilostazol have increased the risk of death in patients with [[congestive heart failure]], studies of significant size have not addressed people without the disease.
{{PAGENAME}} is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown <span style="background:#000000;">'''[[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|here}}]]'''</span>. Common adverse reactions include _______.
 
==Adult Indications and Dosage==
 
===FDA-Labeled Indications and Dosage (Adult)===
 
=====Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
===Off-Label Use and Dosage (Adult)===
 
====Guideline-Supported Use====
 
=====Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
====Non–Guideline-Supported Use====
 
=====Condition 1=====
 
* Dosing Information
 
:* There is limited information about ''Off-Label Non–Guideline-Supported Use'' of {{PAGENAME}} in adult patients.
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
 
==Pediatric Indications and Dosage==
 
===FDA-Labeled Indications and Dosage (Pediatric)===
 
=====Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
===Off-Label Use and Dosage (Pediatric)===
 
====Guideline-Supported Use====
 
=====Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
====Non–Guideline-Supported Use====
 
=====Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
 
==Contraindications==
 
* Condition 1
* Condition 2
* Condition 3
* Condition 4
* Condition 5
 
==Warnings==
 
=====Conidition 1=====
 
(Description)
 
=====Conidition 2=====
 
(Description)
 
=====Conidition 3=====
 
(Description)
 
==Adverse Reactions==
 
===Clinical Trials Experience===
 
=====Condition 1=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
=====Condition 2=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
===Postmarketing Experience===
 
(Description)
 
==Drug Interactions==
 
* Drug 1
* Drug 2
* Drug 3
* Drug 4
* Drug 5
 
=====Drug 1=====
 
(Description)
 
=====Drug 2=====
 
(Description)
 
=====Drug 3=====
 
(Description)
 
=====Drug 4=====
 
(Description)
 
=====Drug 5=====
 
(Description)
 
==Use in Specific Populations==
 
====Pregnancy====
 
* '''[[Pregnancy category#United States|Pregnancy Category (FDA)]]: X'''
 
* '''[[Pregnancy category#Australia|Pregnancy Category (AUS)]]: {{PAGENAME}} is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.'''
 
(Description)
 
====Labor and Delivery====
 
(Description)
 
====Nursing Mothers====
 
(Description)
 
====Pediatric Use====
 
(Description)
 
====Geriatric Use====
 
(Description)
 
====Gender====
 
(Description)
 
====Race====
 
(Description)
 
====Renal Impairment====
 
(Description)
 
====Hepatic Impairment====
 
(Description)
 
====Carcinogenesis, Mutagenesis, Impairment of Fertility====
 
(Description)
 
====Immunocompromised Patients====
 
(Description)
 
====Miscellaneous====
 
(Description)
 
==Administration and Monitoring==
 
====Administration====
 
(Oral/Intravenous/etc)
 
====Monitoring====
 
=====Condition 1=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 2=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 3=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
==IV Compatibility==
 
===Solution===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Y-Site===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Admixture===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Syringe===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===TPN/TNA===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
==Overdosage==
 
===Acute Overdose===
 
====Signs and Symptoms====
 
(Description)
 
====Management====
 
(Description)
 
===Chronic Overdose===
 
====Signs and Symptoms====
 
(Description)
 
====Management====
 
(Description)
 
==Pharmacology==
 
{{Drugbox2
| verifiedrevid =
| IUPAC_name =
| image =
| drug_name =
 
<!--Clinical data-->
| tradename =
| MedlinePlus =
| licence_US =
| pregnancy_AU =
| pregnancy_US =
| legal_status =
| routes_of_administration =
 
<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
 
<!--Identifiers-->
| CAS_number_Ref =
| CAS_number =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID =
| UNII_Ref =
| UNII =
| KEGG_Ref =
| KEGG =
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =
 
<!--Chemical data-->
| C= | H= | N= | O=
| molecular_weight =
| smiles =
| InChI =
| InChIKey =
| StdInChI_Ref =
| StdInChI =
| StdInChIKey_Ref =
| StdInChIKey =
| melting_point =
}}
 
===Mechanism of Action===
 
(Description)
 
===Structure===
 
(Description with picture)
 
===Pharmacodynamics===
 
(Description)
 
===Pharmacokinetics===
 
(Description)
 
===Nonclinical Toxicology===
 
(Description)
 
==Clinical Studies==
 
=====Condition 1=====
 
(Description)
 
=====Condition 2=====
 
(Description)
 
=====Condition 3=====
 
(Description)
 
==How Supplied==
 
(Description)
 
* National Drug Code (NDC):
* Storage:
* Manufactured by: 
* Distributed by:
 
==Images==
 
===Drug Images===
 
{|
| [[File:PILLIMAGE.jpg|thumb|300px|<p style="text-align: left;">
'''Drug Name''':  <BR>
'''Ingredient(s)''':  <BR>
'''Imprint''':  <BR>
'''Color(s)''':  <BR>
'''Shape''':  <BR>
'''Size (mm)''':  <BR>
'''Score''':  <BR>
'''Drug Label Author''':  ]]</p>
|}
 
===Package and Label Display Panel===
 
(Package Images)
 
(Display Panel Images)
 
==Patient Information==
 
===Patient Information from FDA===
 
(Patient Counseling Information)
 
===Patient Information from NLM===
 
(Link to patient information page)
 
==Precautions with Alcohol==
 
Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


Cilostazol is a [[phosphodiesterase inhibitor]] with therapeutic focus on [[Cyclic adenosine monophosphate|cAMP]].  It inhibits platelet aggregation and is a direct arterial vasodilator.  Its main effects are dilation of the [[artery|arteries]] supplying [[blood]] to the legs and decreasing [[platelet]] [[coagulation]].
==Brand Names==


==Category==
Brand Names®
[[Phosphodiesterase inhibitors]].


==US Brand Names==
==Look-Alike Drug Names==
'''PLETAL<sup>®</sup>, Cilostazol<sup>®</sup>.'''


==FDA Package Insert==
* (Paired Confused Name 1a) — (Paired Confused Name 1b)
===PLETAL<sup>®</sup>===
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
'''  [[Cilostazol indications and usage|Indications and Usage]]'''
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
'''| [[Cilostazol dosage and administration|Dosage and Administration]]'''
'''| [[Cilostazol dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Cilostazol contraindications|Contraindications]]'''
'''| [[Cilostazol precautions| Precautions]]'''
'''| [[Cilostazol adverse reactions|Adverse Reactions]]'''
'''| [[Cilostazol drug interactions|Drug Interactions]]'''
'''| [[Cilostazol use in specific populations|Use in Specific Populations]]'''
'''| [[Cilostazol overdosage|Overdosage]]'''
'''| [[Cilostazol description|Description]]'''
'''| [[Cilostazol clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Cilostazol nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Cilostazol clinical studies|Clinical Studies]]'''
'''| [[Cilostazol how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Cilostazol patient counseling information|Patient Counseling Information]]'''
'''| [[Cilostazol labels and packages|Labels and Packages]]'''


==Mechanism of Action==
==[http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm Drug Shortage Status]==
The mechanism of the effects of PLETAL on the symptoms of [[intermittent claudication]] is not fully understood. PLETAL and several of its metabolites are cyclic AMP ([[cAMP]]) [[phosphodiesterase]] III inhibitors (PDE III inhibitors), inhibiting [[phosphodiesterase]] activity and suppressing [[cAMP]] degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively.


PLETAL reversibly inhibits platelet aggregation induced by a variety of stimuli, including [[thrombin]], [[ADP]], [[collagen]], [[arachidonic acid]], [[epinephrine]], and [[shear stress]]. Effects on circulating plasma lipids have been examined in patients taking PLETAL. After 12 weeks, as compared to placebo, PLETAL 100 mg b.i.d. produced a reduction in [[triglycerides]] of 29.3 mg/dL (15%) and an increase in [[HDL-cholesterol]] of 4.0 mg/dL (~10%).
==[http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price Price]==


==References==
==References==


{{Reflist|2}}
{{reflist}}
[[Category:Cardiovascular Drugs]]
 
[[Category:Drugs]]
</div>

Revision as of 17:44, 1 April 2014

Cilostazol detailed information®
Black Box Warning
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration and Monitoring
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient information
Precautions with Alcohol
Brand Names
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For information about (Generic Name), click here.

Synonyms / Brand Names:

Disclaimer

WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer here.

Black Box Warning

FDA Package Insert for Cilostazol detailed information contains no information regarding Black Box Warning.

WARNING

See full prescribing information for complete boxed warning.

Condition Name: (Content)

Overview

Cilostazol detailed information is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown here. Common adverse reactions include _______.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • There is limited information about Off-Label Non–Guideline-Supported Use of Cilostazol detailed information in adult patients.
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Conidition 1

(Description)

Conidition 2

(Description)

Conidition 3

(Description)

Adverse Reactions

Clinical Trials Experience

Condition 1
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 2
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

Postmarketing Experience

(Description)

Drug Interactions

  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description)

Use in Specific Populations

Pregnancy

  • Pregnancy Category (AUS): Cilostazol detailed information is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.

(Description)

Labor and Delivery

(Description)

Nursing Mothers

(Description)

Pediatric Use

(Description)

Geriatric Use

(Description)

Gender

(Description)

Race

(Description)

Renal Impairment

(Description)

Hepatic Impairment

(Description)

Carcinogenesis, Mutagenesis, Impairment of Fertility

(Description)

Immunocompromised Patients

(Description)

Miscellaneous

(Description)

Administration and Monitoring

Administration

(Oral/Intravenous/etc)

Monitoring

Condition 1

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

IV Compatibility

Solution

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Y-Site

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Admixture

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Syringe

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

TPN/TNA

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Overdosage

Acute Overdose

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description)

Pharmacology

Cilostazol detailed information
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Mechanism of Action

(Description)

Structure

(Description with picture)

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

Condition 1

(Description)

Condition 2

(Description)

Condition 3

(Description)

How Supplied

(Description)

  • National Drug Code (NDC):
  • Storage:
  • Manufactured by:
  • Distributed by:

Images

Drug Images

File:PILLIMAGE.jpg

Drug Name:
Ingredient(s):
Imprint:
Color(s):
Shape:
Size (mm):
Score:
Drug Label Author:

Package and Label Display Panel

(Package Images)

(Display Panel Images)

Patient Information

Patient Information from FDA

(Patient Counseling Information)

Patient Information from NLM

(Link to patient information page)

Precautions with Alcohol

Alcohol-Cilostazol detailed information interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Brand Names®

Look-Alike Drug Names

  • (Paired Confused Name 1a) — (Paired Confused Name 1b)
  • (Paired Confused Name 2a) — (Paired Confused Name 2b)
  • (Paired Confused Name 3a) — (Paired Confused Name 3b)

Drug Shortage Status

Price

References

Retrieved from "https://www.wikidoc.org/index.php?title=Cilostazol_detailed_information&oldid=961561"